U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07940790) titled 'A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.' on Nov. 11.
Brief Summary: This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes ...